FDA — authorised 27 September 2024
- Application: NDA215168
- Marketing authorisation holder: GE HLTHCARE
- Indication: Type 1 - New Molecular Entity
- Status: approved
🇺🇸 FLURPIRIDAZ F 18 in United States
FDA authorised FLURPIRIDAZ F 18 on 27 September 2024
Marketing authorisation
FLURPIRIDAZ F 18 in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is FLURPIRIDAZ F 18 approved in United States?
Yes. FDA authorised it on 27 September 2024.
Who is the marketing authorisation holder for FLURPIRIDAZ F 18 in United States?
GE HLTHCARE holds the US marketing authorisation.